Literature DB >> 35707147

Application of Rapidly Accelerating Fibrosarcoma Protein Degraders in Drug Discovery.

Robert B Kargbo1.   

Abstract

Entities:  

Year:  2022        PMID： 35707147      PMCID： PMC9190287          DOI： 10.1021/acsmedchemlett.2c00210

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  6 in total

Review 1.  Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy.

Authors:  Yihui Song; Shu Wang; Min Zhao; Xinyu Yang; Bin Yu
Journal:  J Med Chem       Date:  2022-02-14       Impact factor: 7.446

Review 2.  Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.

Authors:  Andreas M Schmitt; Lucy Dumas; James Larkin
Journal:  Expert Rev Anticancer Ther       Date:  2022-01-02       Impact factor: 4.512

Review 3.  Clinical considerations for the design of PROTACs in cancer.

Authors:  Cristina Nieto-Jiménez; Esther Cabañas Morafraile; Carlos Alonso-Moreno; Alberto Ocaña
Journal:  Mol Cancer       Date:  2022-03-07       Impact factor: 27.401

Review 4.  BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective.

Authors:  Ningning Yan; Sanxing Guo; Huixian Zhang; Ziheng Zhang; Shujing Shen; Xingya Li
Journal:  Front Oncol       Date:  2022-03-31       Impact factor: 6.244

Review 5.  Advances in targeted therapy in non-small cell lung cancer with actionable mutations and leptomeningeal metastasis.

Authors:  Ding Li; Zhenguo Song; Bingqi Dong; Wenping Song; Cheng Cheng; Yongna Zhang; Wenzhou Zhang
Journal:  J Clin Pharm Ther       Date:  2021-07-26       Impact factor: 2.512

Review 6.  PROTAC targeted protein degraders: the past is prologue.

Authors:  Miklós Békés; David R Langley; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2022-01-18       Impact factor: 112.288
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.